Peptide comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are both research peptides. This side-by-side compares their mechanism, typical research dosing, half-life, routes and safety so you can see how they differ. For research use only.
| BPC-157 | TB-500 | |
|---|---|---|
| Category | Recovery | Recovery |
| Overview | A synthetic gastric pentadecapeptide studied for tissue repair. Evidence is largely preclinical; human data is minimal. Research use only. | Synthetic actin-binding peptide studied for tissue repair; strong preclinical data but limited human evidence for musculoskeletal use. |
| How it works | BPC-157's proposed mechanism is not fully established, and most pathway data come from animal and cell models. The most consistently reported action is promotion of angiogenesis (new blood-vessel formation), apparently by upregulating VEGF and signaling through the VEGFR2-Akt-eNOS axis, which increases nitric oxide availability. It is also reported to modulate the nitric oxide (NO) system more broadly, influence ERK1/2 and FAK-paxillin signaling involved in fibroblast migration and tendon-cell outgrowth, and exert cytoprotective and anti-inflammatory effects on the gastrointestinal lining and other tissues. Some work suggests interaction with growth-hormone receptor expression and the dopaminergic and serotonergic systems via the gut-brain axis. Several effects follow a bell-shaped dose-response in animal models, meaning higher doses are not necessarily more effective. These mechanisms are plausible but should be considered provisional given the limited human validation. | Thymosin Beta-4 is a primary intracellular G-actin sequestering peptide: it binds monomeric actin and regulates actin polymerization, which governs cell motility. Through this and related pathways, Tβ4 promotes the migration of fibroblasts, endothelial cells, keratinocytes, and stem/progenitor cells to sites of injury. Preclinical work attributes its repair activity to several effects: stimulating angiogenesis (new blood vessel formation), reducing inflammatory cytokine signaling, decreasing apoptosis in injured tissue, and increasing collagen deposition during wound healing. The "TB-500" fragment is thought to retain the actin-binding and cell-migration-promoting properties, but the relative potency of fragment versus full-length peptide in humans is not well characterized. |
| Half-life | Very short systemically: animal pharmacokinetic data show an elimination half-life under ~30 minutes (~15 min in rats, ~5 min in dogs) after IV dosing, undetectable by ~4 hours. Despite this, biological effects are reported to outlast plasma presence (a PK-PD disconnect). Human half-life is not formally characterized. | Full-length recombinant Tβ4 showed a short plasma terminal half-life of ~0.5-2 hours after IV dosing in a Phase I study; tissue/biological effects may outlast plasma levels. Half-life of the subcutaneous 'TB-500' fragment in humans is not well characterized. |
| Dosing reference | No established or regulator-approved clinical dosing in humans. Published human data are limited to a few small pilot studies (e.g., localized bladder injection for interstitial cystitis; intra-articular/peri-articular injection for knee pain; a small IV tolerability report up to 20 mg). These are too small and heterogeneous to define a validated therapeutic dose, and no consensus clinical protocol exists. | No established clinical dosing for recovery/musculoskeletal use in humans. Investigational use of full-length recombinant Tβ4 in a first-in-human Phase I study used single intravenous doses escalated from 0.05-25 ug/kg and a multiple-dose arm of 0.5-5.0 ug/kg IV daily for 10 days. Eye indications have used a topical 0.1% ophthalmic solution (RGN-259). These are research settings only and do not translate to the subcutaneous protocols used by the community. |
| Routes | subcutaneous, intramuscular, oral | subcutaneous, intramuscular, topical, nasal |
| Safety & side effects | Long-term human safety has not been established; there are no large or long-duration human trials. Preclinical toxicology and the few human reports describe a generally favorable short-term tolerability profile with no identified lethal dose in animals, and small human studies reported few adverse events. However, theoretical concerns remain, most notably that strong angiogenesis promotion could be undesirable in the presence of tumors or cancer risk; this has not been adequately studied. Community reports include injection-site reactions and, in some individuals, dizziness, vertigo, racing heart, headache, fatigue, brain fog, or anxiety/panic-like episodes after dosing. Product quality is a major real-world risk: research-grade material is unregulated and may be impure, mislabeled, or contaminated. BPC-157 is not FDA-approved, is excluded from FDA compounding, and is banned in competitive sport by WADA. This information is for research reference only and is not a recommendation for human use. | Human safety data is limited and largely from investigational full-length Tβ4. Early-phase IV studies in healthy volunteers reported only mild-to-moderate adverse events, no serious adverse events or dose-limiting toxicities, and minimal immunogenicity. Community-reported side effects (anecdotal) include transient fatigue/lethargy, mild headache, injection-site irritation, and water retention when stacked with growth-hormone secretagogues. Because TB-500 is sold as an unregulated research chemical, product identity, purity, and sterility are not guaranteed, which is a meaningful real-world risk. Theoretical concerns about pro-angiogenic peptides and tumor growth have not been resolved in long-term human data. TB-500 is prohibited in competitive sport under WADA. Not approved for human use; consult a qualified clinician before any use. |
For research use only. Not for human consumption. Always verify against current literature.